June 27, 2011 11:08 ET

Newly Approved Therapies for Prostate Cancer Shift Treatment Dynamics

ROCKVILLE, MD--(Marketwire - Jun 27, 2011) - has announced the addition of the new report, "R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant disease," to their collection of Therapeutic Area market reports. For more information, visit

Targeted therapies dominate the prostate cancer pipeline. However, developers will face strong competition from recently approved therapies. The advancement in understanding the molecular basis of prostate cancer has exposed new targets, but companies must identify the correct ones to improve the chances of success.

Clinical trial design must demonstrate the clinical efficacy of novel therapies. The selection of correct patient populations, trial duration, and endpoints is becoming increasingly important in the era of target therapy development.

New therapies will have to focus on improving overall survival in advanced, castrate-resistant disease, particularly when other therapies have been exhausted. They must be superior to the current standard of care, Taxotere (docetaxel; Sanofi).

Features and benefits of the report:

  • In-depth analysis of the prostate cancer pipeline - development stage, therapeutic class, molecular targets, and changes in pipeline since 2009
  • In-depth analysis of current comparator therapy - target product profile, unmet needs, and innovative early-stage approaches
  • In-depth analysis of clinical trial design - patient selection, duration, clinical endpoints, and future developments in trial design
  • The future of prostate cancer treatment - improving biomarkers, and novel targeted therapies

Key questions answered:

  • Understand how the dynamics of prostate cancer treatment are changing as a result of newly emerging therapies
  • Identify the target product profile for new therapies and innovative early-stage drug targets in relation to the current standard of care
  • Assess the potential for new innovative approaches to treating prostate cancer and obstacles that may affect their development

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact